Kallmann Syndrome
Conditions
Keywords
Kallmann Syndrome, hypogonadotropic hypogonadism
Brief summary
Objective is to characterize epidemiology, clinical and genetic features of Kallmann syndrome in Finland.
Detailed description
Kallmann syndrome is comprised of idiopathic hypogonadotropic hypogonadism and anosmia (inability to smell). Associated phenotypes may include cryptorchidism, microphallus, bone deformations, mirror movements, hearing loss and infertility. Objective is to characterize epidemiology, clinical and genetic features of Kallmann syndrome in Finland.
Interventions
DRUGShort withdrawal of testosterone, gonadotropins or estrogenic compounds (see below)
clinical examination, biochemical profile, and genetic characterization. Possibility to stop hormone therapy with drugs containing testosterone (Atmos®, Testim®, Testogel®, Nebido®, Panteston®, Sustanon®), FSH (Gonal-F®, Puregon®), hCG (Pregnyl®), estrogenic compounds (such as Estrofem®, Divigel®, Estrena®, Climara®, Estradot®, Evorel®, Femseven®: Merimono®, Progynova®, Ovestin®, Zumenon®, Estrogel®, Femoston®, Femoston combi®, Divina®, Divitren®, Indivina®, Estalis sekvens®, Evorel sequi®, Novofem®, Trisekvens®, Activelle®, Estalis®, Evorel conti®, Kliogest®, Mericomb®, Mericomb Mite®, Merigest®: Angeliq®) for 3 mo to assess reversibility of GnRH-deficiency will be offered.
Sponsors
Hospital for Children and Adolescents, Finland
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
15 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Kallmann syndrome * Age 15 yrs or more
Exclusion criteria
* Severe mental retardation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical features including quality of life, reversibility and genetic features of Kallmann syndrome in Finland | 0, 3 mo and during subsequent F/U |
Secondary
| Measure | Time frame |
|---|---|
| epidemiology | by 2012 (anticipated) |
Countries
Finland
Outcome results
None listed